文献速递白血病MDS 与骨髓增殖性肿瘤

突变型SETBP1增强NRAS驱动的MAPK通路激活促进侵袭性白血病

Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia.
PubMed 文献 · Leukemia · 2021-05-17

研究探讨SETBP1突变如何调节Ras驱动白血病的生物学。发现SETBP1与Ras通路突变共表达时促进小鼠骨髓体外恶性转化和体内侵袭性髓系白血病。SETBP1增强NRAS基因表达特征,上调MAPK信号、下调分化通路,并增强NRAS驱动的MAPK蛋白磷酸化。表达NRAS和SETBP1的细胞对MAPK通路抑制剂敏感,曲美替尼在NRAS/SETBP1突变小鼠模型中 confer 生存获益。

要点

  • SETBP1与Ras通路突变共表达促进小鼠骨髓体外转化和体内侵袭性髓系白血病。
  • SETBP1增强NRAS基因表达特征,上调MAPK信号并下调分化通路。
  • NRAS/SETBP1突变细胞对MEK抑制剂曲美替尼敏感,小鼠模型中有生存获益。

核心结论

  • SETBP1突变通过增强NRAS驱动的MAPK通路激活促进侵袭性白血病,且突变细胞对曲美替尼敏感。

研究设计与样本

  • 研究采用小鼠骨髓体外转化实验和体内白血病模型,结合基因表达和磷酸化分析。

主要发现

  • SETBP1与Ras通路突变共表达促进小鼠骨髓体外恶性转化和体内侵袭性髓系白血病。
  • SETBP1增强NRAS基因表达特征,上调MAPK信号并下调分化通路。
  • SETBP1增强NRAS驱动的MAPK蛋白磷酸化。
  • 表达NRAS和SETBP1的细胞对MAPK通路抑制剂敏感。
  • 曲美替尼在NRAS/SETBP1突变小鼠模型中 confer 生存获益。

关键数值与推荐

  • NRAS/SETBP1突变细胞在体外和体内均对曲美替尼敏感。

临床怎么用

  • 曲美替尼可能用于SETBP1突变疾病,尤其NRAS/SETBP1共突变患者,需进一步临床验证。

局限性

  • 研究主要为小鼠模型和体外实验,尚未在人体中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mutations in SET-binding protein 1 (SETBP1) are associated with poor outcomes in myeloid leukemias. In the Ras-driven leukemia, juvenile myelomonocytic leukemia, SETBP1 mutations are enriched in relapsed disease. While some mechanisms for SETBP1-driven oncogenesis have been established, it remains unclear how SETBP1 specifically modulates the biology of Ras-driven leukemias. In this study, we found that when co-expressed with Ras pathway mutations, SETBP1 promoted oncogenic transformation of murine bone marrow in vitro and aggressive myeloid leukemia in vivo. We demonstrate that SETBP1 enhances the NRAS gene expression signature, driving upregulation of mitogen-activated protein kinase (MAPK) signaling and downregulation of differentiation pathways. SETBP1 also enhances NRAS-driven phosphorylation of MAPK proteins. Cells expressing NRAS and SETBP1 are sensitive to inhibitors of the MAPK pathway, and treatment with the MEK inhibitor trametinib conferred a survival benefit in a mouse model of NRAS/SETBP1-mutant disease. Our data demonstrate that despite driving enhanced MAPK signaling, SETBP1-mutant cells remain susceptible to trametinib in vitro and in vivo, providing encouraging preclinical data for the use of trametinib in SETBP1-mutant disease.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Carratt SA, Braun TP, Coblentz C, et al. Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia. Leukemia. 2021. PMID: 34002029. doi:10.1038/s41375-021-01278-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。